Actigraphy Improvement With Voxelotor (ActIVe) Study

Sickle Cell Disease Clinical Trial

— ActIVe  

Official title:

A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04400487
• Other study ID #: GBT440-039
• Secondary ID: C5341024
• Status: Completed
• Phase: Phase 4
• Start date: December 21, 2020
• Est. completion date: September 13, 2022

Study information

• Verified date: November 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study to evaluate the effect of voxelotor on daily physical activity and sleep quality, as measured by a wrist-worn device in participants with sickle cell disease (SCD) and chronic moderate anemia.

Description:

All participants will receive Voxelotor as treatment. There will be approximately 13 sites in the US.

Participant safety and tolerability will be monitored during the study using standard measures, including physical examinations, vital signs (including temperature, blood pressure, pulse rate, respiratory rate and peripheral oxygen saturation [SpO2]), clinical laboratory tests, and adverse event (AE) monitoring.

Screening Period (up to 4 weeks in duration): During this period, participants will sign the informed consent form (ICF), after which they will complete the screening assessments as detailed in the Schedule of Assessments (SOA).

Run-in Period (2 weeks in duration): During this period, participants will enter a 2-week run-in period (Day -14 to Day -1) during which baseline actigraphy measures of physical activity and sleep quality, overnight pulse oximetry assessments of oxygen saturation, and Patient-Reported Outcome (PRO) assessments will be collected before initiating treatment with voxelotor.

Treatment Period (24 weeks in duration): After completion of the 14-day Run-in Period, participants will enter the open label treatment period and receive voxelotor 1500 mg once daily for 24 weeks. Repeat actigraphy assessments of physical activity and sleep quality, and overnight pulse oximetry will be performed during the treatment period (Weeks 10 to 12 and Weeks 22 to 24). PRO and Clinical Global Impression (CGI) assessments will be completed at scheduled study visits. The open-label treatment period is considered the continuous 24 weeks of voxelotor treatment from date of first dose (Day 1).

Follow-up Period (4 weeks in duration): Immediately following the 24-week treatment period, participants will enter a 4-week Follow-up Period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: September 13, 2022
• Est. primary completion date: September 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Male or female participants with SCA (sickle hemoglobin with two sickle cell genes [HbSS] or sickle hemoglobin (S) and one beta thalassemia gene [HbS ß0] thal genotype)

2. Between 12 to 55 years of age (inclusive)

3. Screening Hb level =8.0 g/dL

4. Treatment with hydroxyurea (HU) therapy on study is permitted if the participant has been on a stable dose for at least 90 days before enrollment with no dose modifications planned or anticipated by the Investigator

5. Treatment with glutamine is permitted

6. Treatment with erythropoiesis-stimulating agents (ESAs) is permitted if the participant has been on a stable dose for at least 12 weeks before enrollment with no dose modifications planned or anticipated by the Investigator

7. Female participants of child-bearing potential must use highly effective methods of contraception to 30 days after the last dose of study drug. Male participants must use barrier methods of contraception to 30 days after the last dose of study drug

8. Females of child-bearing potential are required to have a negative pregnancy test before the administration of study drug

9. Written informed consent and/or parental/guardian consent and participant assent per Institutional Review Board (IRB) policy and requirements, consistent with ICH guidelines

Exclusion Criteria:

1. Red blood cell (RBC transfusion within 3 months before initiation of study drug

2. Planned initiation of regularly scheduled RBC transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) during the study

3. Hospitalization for vaso-occlusive crisis (VOC) or acute chest syndrome (ACS) within 30 days prior to informed consent/assent.

4. More than 10 VOCs requiring hospitalization, emergency department or clinic visit within the past 12 months

5. Planned elective surgery within the next 6 months

6. Physical inactivity attributable to clinically significant musculoskeletal, cardiovascular, or respiratory comorbidities

7. Anemia due to bone marrow failure (eg, myelodysplasia)

8. Absolute reticulocyte count (ARC) < 100 x10^9/L

9. Screening alanine aminotransferase (ALT) > 4× upper limit of normal (ULN)

10. Severe renal dysfunction (estimated glomerular filtration rate [GFR] < 30 mL/min/1.73 m2 by Schwartz formula) or is on chronic dialysis

11. Known active hepatitis A, B or C or known to be human immunodeficiency virus (HIV)-positive.

12. Females who are breast-feeding or pregnant

13. Major surgery within 8 weeks before enrollment. Participants must have completely recovered from any previous surgery before enrollment

14. History of hematopoietic stem cell transplant or gene therapy

15. Received an investigational drug within 30 days or 5-half-lives, whichever is longer, prior to consent, or is currently participating in another trial of an investigational or marketed drug (or medical device)

16. Use of concomitant medications (eg, crizanlizumab) that confound the ability to interpret data from the study

17. Medical, psychological, or behavioral condition that, in the opinion of the Investigator, would confound or interfere with evaluation of safety and/or efficacy of the study drug, prevent compliance with the study protocol; preclude informed consent; or, render the participant unable/unlikely to comply with the study procedures

18. Use of herbal medications (e.g., St. John's Wort), sensitive cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic index, strong CYP3A4 inhibitors, fluconazole, or moderate or strong CYP3A4 inducers

19. Symptomatic coronavirus disease of 2019 (COVID-19) infection

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Anemia
• Sickle Cell Disease

Intervention

Drug:
• Voxelotor
500 mg Tablet, Oral, With or Without Food

Locations

Country	Name	City	State
United States	Children's Healthcare of Atlanta	Atlanta	Georgia
United States	The Children's Hospital at Montefiore	Bronx	New York
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Children's Hospital of Michigan	Detroit	Michigan
United States	Duke Department of Pediatrics	Durham	North Carolina
United States	UConn Health	Farmington	Connecticut
United States	The University of Texas Health Science Center at Houston	Houston	Texas
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	VCU Health	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Total Daily Physical Activity (Counts Per Minute) to Week 10-12	Daily physical activity was measured by actigraphy in participants with sickle cell disease (SCD) and chronic moderate anemia. Actigraphy assessments were performed using wrist-worn tri-axial accelerometry device. Actigraphy is an accepted methodology for tracking activity levels, time spent in moderate and vigorous physical activity, step counts, and energy expenditure. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 10-12
Primary	Change From Baseline in Total Daily Physical Activity (Counts Per Minute) to Week 22-24	Daily physical activity was measured by actigraphy in participants with SCD and chronic moderate anemia. Actigraphy assessments were performed using wrist-worn tri-axial accelerometry device. Actigraphy is an accepted methodology for tracking activity levels, time spent in moderate and vigorous physical activity, step counts, and energy expenditure. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 22-24
Primary	Change From Baseline in Light Physical Activity to Week 10-12	Change in daily physical activity was measured by actigraphy in adolescent and adult participants with SCD and chronic moderate anemia. This outcome measure described the change from baseline in light physical activity. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 10-12
Primary	Change From Baseline in Light Physical Activity to Week 22-24	Change in daily physical activity was measured by actigraphy in adolescent and adult participants with SCD and chronic moderate anemia. This outcome measure described the change from baseline in light physical activity. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 22-24
Primary	Change From Baseline in Moderate Physical Activity to Week 10-12	Change in daily moderate physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 10-12
Primary	Change From Baseline in Moderate Physical Activity to Week 22-24	Change in daily moderate physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 22-24
Primary	Change From Baseline in Vigorous Physical Activity to Week 10-12	Change in daily vigorous physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 10-12
Primary	Change From Baseline in Vigorous Physical Activity to Week 22-24	Change in daily vigorous physical activity (minutes per day) was measured by actigraphy in participants with SCD and chronic moderate anemia. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 22-24
Primary	Change From Baseline in Total Nocturnal Sleep Time to Week 10-12	Total nocturnal sleep time was measured by overnight actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 10-12
Primary	Change From Baseline in Total Nocturnal Sleep Time to Week 22-24	Total nocturnal sleep time was measured by overnight actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 22-24
Primary	Change From Baseline in Wake Time After Sleep Onset to Week 10-12	Measured by actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 10-12
Primary	Change From Baseline in Wake Time After Sleep Onset to Week 22-24	Measured by actigraphy monitoring. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments. In this outcome measure the average of at least 8 valid days during the specified two-week period was considered. A participant's daily wear must be 18 hours or more in a day to be considered a valid day.	Baseline, Week 22-24
Primary	Change From Baseline in Sleep Efficiency to Week 10-12	Sleep efficiency was defined as ration of total sleep time to time in bed. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments.	Baseline, Week 10-12
Primary	Change From Baseline in Sleep Efficiency to Week 22-24	Sleep efficiency was defined as ration of total sleep time to time in bed. Change from baseline to follow-up visit was calculated as the baseline measurement subtracted from the follow-up measurement for all assessments.	Baseline, Week 22-24
Primary	Percentage of Participants With a More Than (>)1 Grams Per Deciliter (g/dL) Increase in Hemoglobin (Hb) at Week 12		Week 12
Primary	Percentage of Participants With a >1 g/dL Increase in Hemoglobin (Hb) at Week 24		Week 24
Primary	Change From Baseline in Mean Overnight Oxygen Saturation (SpO2 Percentage [%]) to Week 10-12		Baseline, Week 10-12
Primary	Change From Baseline in Mean Overnight SpO2 % to Week 22-24		Baseline, Week 22-24
Primary	Change From Baseline in Median Number of Overnight SpO2 Dips > 3% Per Hour to Week 10-12		Baseline, Week 10-12
Primary	Change From Baseline in Median Number of Overnight SpO2 Dips > 3% Per Hour to Week 22-24		Baseline, Week 22-24

External Links

•   To obtain contact information for a study center near you, click here.